UNSPSC 51162642: Oxeladin citrate

This classification denotes an antitussive agent with the molecular formula C20H33NO3.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5AEV5C340C, chemically known as benzeneacetic acid, .alpha.,.alpha.-diethyl-, 2-(2-(diethylamino)ethoxy)ethyl ester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1), but more generally known as oxeladin citrate, which bears US NIH Compound Identifier 40384.

European Medicines Agency schedules oxeladin citrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09513MIG. Most nations, for tariff purposes, schedule oxeladin citrate under HS 29221980. SMILES: CCC(CC)(C1CCCCC1)C(=O)OCCOCCN(CC)CC.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51162642 Oxeladin citrate is a Commodity code that in recent state and local practice encompasses naloxone, drug deactivation systems, and generic multi-source pharmaceuticals procured by health departments, county health agencies, and cooperative purchasing alliances to support community health initiatives and emergency medical response. Oxeladin citrate, a cough suppressant, appears tangentially or nominally in these opportunities; the actual procurement focus is opioid antagonists and pharmaceutical distribution systems rather than the specific active pharmaceutical ingredient named in the code. State and local issuing bodies under this code span county health departments, state pharmacy programs, and multistate cooperative purchasing vehicles. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, are recent active buyers.

Seminole County issued IFB 60459723LAS on June 30, 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida; response deadline was July 26, 2023. MMCAP issued RFP S1070000015802 on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness of July 1, 2026. The MMCAP procurement weights price competitiveness at 75 percent of evaluation and requires vendors to maintain contractual relationships with authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Recent activity is concentrated in Florida and the upper Midwest, with MMCAP's multistate footprint spanning at least Minnesota and Oregon.